SG
XBI icon

Sankala Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Sankala Group’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.3K Hold
150
– – 0.01% 321
2025
Q4 		$19.1K Buy
+150
New +$17.2K 0.02% 321

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sankala Group's XBI Position: Q1 2026 in Review

Sankala Group held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 150 shares worth $18.3K. The position accounts for 0.01% of the portfolio, ranked #321.

Sankala Group first reported a position in XBI in Q4 2025 and has held it in 2 quarters since. The position peaked at $19.1K in Q4 2025. 815 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Sankala Group held 150 shares of State Street SPDR S&P Biotech ETF worth $18.3K as of Q1 2026.
  • Sankala Group left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
  • State Street SPDR S&P Biotech ETF made up 0.01% of Sankala Group's portfolio in Q1 2026, its #321 holding.
  • Sankala Group first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 2 quarters since.
  • Sankala Group's State Street SPDR S&P Biotech ETF position peaked at $19.1K in Q4 2025.
  • 815 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Sankala Group's 13F filing for Q1 2026, filed 31 Mar 2026.